Smac-derived Aza-peptide As an Aminopeptidase-resistant XIAP BIR3 Antagonist

Mohamed A. Elsawy, Irina G. Tikhonova, Lorraine Martin, Brian Walker

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
343 Downloads (Pure)


The peptidic nature of anti-IAPs N-terminus Smac-derived peptides precludes their utilization as potential therapeutic anticancer agents. Recent advances in the development of novel Smac-derived peptidomimetics and non-peptidic molecules with improved anti-IAPs activity and resistance to proteolytic cleavage have been reported and led to a number of candidates that are currently in clinical trials including LCL-161, SM-406/AT-406, GDC-0512/GDC-0917, and birinapant. As an attempt to improve the proteolytic stability of Smac peptides, we developed the Aza-peptide AzaAla-Val-Pro-Phe-Tyr-NH2 (2). Unlike unmodified peptide Ala-Val-Pro-Phe-Tyr-NH2 (1), analogue (2) exhibited resistance towards proteolytic cleavage by two aminopeptidases; LAP and DPP-IV, while retaining its IAP inhibitory activity. This was due to the altered planar geometry of the P1 residue side chain. Our findings showed that using aza-isosteres of bioactive peptide sequences imbue the residue with imperviousness to proteolysis; underscoring a potential approach for developing a new generation of Smac-derived Aza-peptidomimetics.

Original languageEnglish
Pages (from-to)836-843
Number of pages8
JournalProtein and Peptide Letters
Issue number9
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Smac-derived Aza-peptide As an Aminopeptidase-resistant XIAP BIR3 Antagonist'. Together they form a unique fingerprint.

Cite this